Nakagaito M, Imamura T, Joho S, et al. - Researchers examined the factors associating with the renoprotection of sodium-glucose cotransporter 2 inhibitor (SGLT2i) therapy for the patients suffering from heart failure (HF) and type 2 diabetic mellitus (T2DM), in this single-center, non-randomized, open-labeled, prospective registry study. Factors that were independently linked with elevations in estimated glomerular filtration rate (eGFR) during follow-up were: lower plasma B-type natriuretic peptide (BNP) level and the use of renin-angiotensin system inhibitor (RASI). Regardless of baseline HbA1c concentrations, significant increases in eGFR were seen in patients with both low plasma BNP levels and uses of RASI. Thus, lower plasma BNP concentration and the use of RASI at baseline were revealed as two key contributors to the SGLT2i-induced renoprotective impacts in patients suffering from decompensated HF and T2DM.